MAPT and dementia: In our comprehensive evaluation of five CSF biomarkers across four clinical scoring algorithms, we demonstrate the consistently superior performance of the Tau/Aβ(1–42) ratios compared with single biomarkers for prediction of clinical decline and conversion to dementia.